A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China

This study has been terminated.
(This study was prematurely terminated due to low enrollment)
Sponsor:
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT01464021
First received: October 31, 2011
Last updated: February 3, 2014
Last verified: February 2014

October 31, 2011
February 3, 2014
December 2011
December 2012   (final data collection date for primary outcome measure)
Number of Participants With at Least a Moderate European League Against Rheumatism (EULAR) Response [ Time Frame: Week 12 ] [ Designated as safety issue: No ]

A EULAR response reflects improvement in disease activity and attainment of a lower degree of disease activity based on the Disease Activity Score (DAS)28 score. The DAS28 score ranges from 0-10, with higher scores indicating more disease activity.

A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score of less than or equal to 3.2.

A Moderate Response is defined as either:

an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 from Baseline and attainment of a DAS28 score of less than or equal to 5.1 or, an improvement (decrease) in the DAS28 of more than 1.2 from Baseline and attainment of a DAS28 score of greater than 3.2.

No Response is defined as either an improvement (decrease) in the DAS28 of less than or equal to 0.6, or an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 of more than 5.1

The percentage of patients with at least a moderate EULAR(European League Against Rheumatism) response at week 12 [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01464021 on ClinicalTrials.gov Archive Site
  • Percent Change From Baseline in Disease Activity Score (DAS)28 Erythrocyte Sedimentation Rate (ESR) [ Time Frame: Weeks 4, 8, 12, 26 ] [ Designated as safety issue: No ]
    The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, erythrocyte sedimentation rate (ESR), and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score > 5.1 indicates high disease activity, ≤ 5.1 indicates moderate disease activity, ≤ 3.2 indicates low disease activity, and ≤ 2.6 indicates clinical remission.
  • Percent Change From Baseline in Tender and Swollen Joint Counts [ Time Frame: Weeks 4, 8, 12, 26 ] [ Designated as safety issue: No ]
    Change in number of tender joints and swollen joints for 28 assessed joints.
  • Percent Change From Baseline in C-reactive Protein [ Time Frame: Weeks 4, 8, 12, 26 ] [ Designated as safety issue: No ]
    C-reactive protein level in serum (mg/dL)
  • Percent Change From Baseline in Erythrocyte Sedimentation Rate (ESR) [ Time Frame: Weeks 4, 8, 12, 26 ] [ Designated as safety issue: No ]
    Rate at which red blood cells sediment in a period of 1 hour, a non-specific measure of inflammation; a higher rate = more inflammation.
  • Percent Change From Baseline in Patient's Global Assessment of Disease Activity [ Time Frame: Weeks 4, 8, 12, 26 ] [ Designated as safety issue: No ]
    A horizontal Visual Analog Scale (VAS) (100 mm) measure of the participant's global assessment of RA disease activity, where the participant was asked to place a vertical mark on the line to indicate how well their RA has been within the last 24 hours, ranging from 0 mm (very well) to 100 mm (very poorly).
  • Percent Change From Baseline in Patient's Assessment of Pain [ Time Frame: Weeks 4, 8, 12, 26 ] [ Designated as safety issue: No ]
    A horizontal VAS (100 mm) measure of the participant's assessment of RA pain, where the participant was asked to place a vertical mark on the line to indicate how much pain they have had due to RA in the past week, ranging from 0 mm (no pain) to 100 mm (pain as bad as it could be).
  • Percent Change From Baseline in Physician's Global Assessment of RA Disease Activity [ Time Frame: Weeks 4, 8, 12, 26 ] [ Designated as safety issue: No ]
    A horizontal VAS (100 mm) measure of the physician's global assessment of the participant's current RA disease activity, ranging from 0 mm (very good condition) to 100 mm (very bad condition).
  • Percent Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) [ Time Frame: Weeks 4, 8, 12, 26 ] [ Designated as safety issue: No ]
    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3).
  • Change in DAS(Disease Activity Score)28(ESR) at all timepoints compared to Baseline [ Time Frame: Baseline, Weeks 4, 8, 12, 26, 38 and 52/Early Termination ] [ Designated as safety issue: No ]
  • Change in tender and swollen joint count at all timepoints compared to Baseline [ Time Frame: Baseline, Weeks 4, 8, 12, 26, 38 and 52/Early Termination ] [ Designated as safety issue: No ]
  • Change in C-reactive protein (CRP) at all timepoints compared to Baseline [ Time Frame: Baseline, Weeks 4, 8, 12, 26, 38 and 52/Early Termination ] [ Designated as safety issue: No ]
  • Change in Erythrocyte Sedimentation Rate (ESR) at all timepoints compared Baseline [ Time Frame: Baseline, Weeks 4, 8, 12, 26, 38 and 52/Early Termination ] [ Designated as safety issue: No ]
  • Change in Patient's Global Assessment of Disease Activity at all timepoints compared to Baseline [ Time Frame: Baseline, Weeks 4, 8, 12, 26, 38 and 52/Early Termination ] [ Designated as safety issue: No ]
  • Change in Patient's Assessment of Pain at all timepoints compared to Baseline [ Time Frame: Baseline, Weeks 4, 8, 12, 26, 38 and 52/Early Termination ] [ Designated as safety issue: No ]
  • Change in Physician's Global Assessment of Disease Activity at all timepoints compared to Baseline [ Time Frame: Baseline, Weeks 4, 8, 12, 26, 38 and 52/Early Termination ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China
A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China

A post-marketing uncontrolled observational study to explore and describe the effectiveness of adalimumab, as prescribed according to the local product label, in patients with moderately to severely active rheumatoid arthritis (RA) in China.

This post-marketing, multi-center, uncontrolled observational study will be conducted in an open-label, non-interventional setting, for RA patients using commercially available adalimumab administered subcutaneously (SC). Adalimumab effectiveness will be assessed based on data from clinic visits beginning at Baseline and continuing per standard of care for RA. The primary objective is to evaluate the effectiveness of adalimumab in improving patients' disease activity measured by Disease Activity Score (DAS28) at Week 12. The maximum observation period for each patient is approximately 52 weeks, as long as the patient continues to receive adalimumab injections. The study was terminated due to low enrollment.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Whole blood, serum

Non-Probability Sample

Chinese adult participants with a diagnosis of rheumatoid arthritis (RA) (any disease duration) who meet the requirements per the local label for treatment with adalimumab. Participants must be naïve to adalimumab at the Baseline visit.

  • Arthritis
  • Rheumatoid
Not Provided
Adalimumab
Chinese adult participants with a diagnosis of rheumatoid arthritis (RA) (any disease duration) who meet the requirements per the local label for treatment with adalimumab. Participants must be naïve to adalimumab at the Baseline visit.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
26
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female patient greater than or equal to 18 years of age with diagnosis of RA (Rheumatoid Arthritis) and no history of chronic arthritis before age 16.
  2. Patient meets the requirements for treatment with adalimumab per the local product label.
  3. Patient is naïve to adalimumab, and has not used any other immunomodulatory biologic* DMARD (Disease Modifying Antirheumatic Drugs) in the past 8 weeks before the Baseline visit (*rituximab may not have been used in the past 104 weeks before the Baseline visit).
  4. Patient must be able and willing to provide written authorization (or informed consent where applicable) to disclose and use personal health information and comply with the requirements of this study protocol as well as agree to data being collected by Abbott.

Exclusion Criteria:

  1. Patient is currently being treated with or has been treated with any investigational drug of chemical or biologic nature within a minimum of 30 days or five half lives (whichever is longer) of the drug prior to the Baseline visit.
  2. Prior clinically active TB (tuberculosis): if patient has had prior clinically active TB, there should be documentation that a full course of appropriate anti-TB therapy was completed or an ongoing full course of appropriate anti-TB therapy has been started before initiation of adalimumab in accordance with the local product label; otherwise, the patient will not be eligible to participate in this study.
  3. Patient who intends to take less than 6 consecutive (every other week) injections of adalimumab.
  4. Patients should not be enrolled if they cannot be treated with adalimumab in accordance with the local product label or if the Investigator determines that they should not be enrolled based on his/her clinical judgment.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
China
 
NCT01464021
P13-194
No
AbbVie ( AbbVie (prior sponsor, Abbott) )
AbbVie (prior sponsor, Abbott)
Not Provided
Study Director: Dawn Carlson AbbVie
AbbVie
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP